Overview

ABEMA Alone or in COMBO With MK-6482

Status:
Recruiting

Trial end date:
2023-02-02

Target enrollment:

Participant gender:

Summary

This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: - Abemaciclib - MK-6482

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Eli Lilly and Company